• Universal to all faith traditions is the call to safeguard our personal health and the health of others as a moral obligation. ICCR’s voice in the national discourse on domestic health care begins with this moral mandate. Adequate health care and the right to security during sickness is guaranteed under Article 25 of the UN Universal Declaration on Human Rights, however these rights are regularly violated and, for those in our nation least able to afford it, access to affordable health care often remains out of reach. As people of faith, we are called to address the injustices of the current health care system; as investors and professionals working in the field, we are called to address its inefficiencies.

    Featured ICCR Initiatives

    Letter to President Bident Urging U.S. Support to Waive Intellectual Property Protections for COVID-19 Vaccines and Treatments.  According to the Bloomberg COVID-19 Vaccine Tracker, as of March 7, 2021, the global vaccination rate is 7.9 million doses per day. At this rate, it will take nearly four years to cover 75% of the world’s population with a two-dose vaccine. For this reason, ICCR members have asked President Biden to support an emergency COVID-19 waiver of World Trade Organization (WTO) intellectual property rules, so that greater supplies of vaccines, treatments, and diagnostic tests can be produced in as many places as possible as quickly as possible. Read the letter here.

    Shareholders Press Pharma Companies Accepting Public Funds to Prioritize Access and Affordability in the Development of Covid Medicine. In December of 2020, ICCR members announced that they filed shareholder proposals at six pharmaceutical companies in an effort to learn how the companies will price COVID medicine developed with public monies.

    Investors urge pharma companies to work collaboratively on Covid-19 response. In April of 2020, ICCR members sent letters to the CEOs of fourteen pharmaceutical companies calling for a collaborative approach in the development of health technologies, including diagnostics, treatments and a vaccine in the global fight against Covid-19.

    Shareholders renew their campaign to curb escalating drug prices in the U.S. The resolutions are the evolution of a multi-year campaign by investors to increase board oversight of risks due to public perceptions around escalating drug prices on key medicines. 

    Investors challenge pay packages at pharma companies, saying they incentivize drug price hikes. Shareholder filed resolutions at Abbvie, Amgen, Biogen, Bristol Myers Squibb and Eli Lilly. 

    The Medicines Patent Pool.   ICCR encourages pharma companies to share patents for their life-saving HIV drug formulations through the Medicines Patent Pool as a way to make them more affordable and available where they are needed most. 

    Featured Resources

    Pandemic Profiteers Exposed: A COVID-19 Pandemic Profits Tax as one essential tool to reverse inequalities and rebuild better post-pandemic. New Oxfam Report

    Imbruvica's Patent Wall: "Drip Feed" patenting lengthens the monopoly on Imbruvica by 9 yearsNew research by I-MAK shows how pharma companies use "drip feed" patenting to artificially lengthen their monopolies.

    Statement of Principles and Recommended Practices for Corporations on Domestic Health Issues. These principles articulate our position on corporate responsibility regarding domestic health care, along with our recommended best practices


    Examining Structural Racism in the Development of Medicine

    Examining Structural Racism in the Development of Medicine

    A Bitter Pill

    Investor's campaign to control drug pricing

    Sign Up for our eNewsletter

    * indicates required